Padmanee Sharma
Runs the platform that studies patients' tumours before and after immunotherapy to learn why checkpoint drugs work or fail.
Medical oncologist and immunologist who pioneered pre-surgical immunotherapy trials to study drug mechanisms in human tissue. Co-leads the Parker Institute site at MD Anderson and the immunotherapy platform with James Allison. Work on ICOS, VISTA, and resistance mechanisms to checkpoint blockade.
| Title | Journal | Year |
|---|---|---|
| Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy | Cell | 2017 |
| The future of immune checkpoint therapy | Science | 2015 |
This paper launched the immunotherapy era. It was the first randomised evidence that taking a brake off the immune system could extend life in a solid cancer, and it introduced clinicians to immune-related adverse events and to responses that arrive late or after apparent progression. Ipilimumab alone has since been superseded by PD-1 antibodies and combinations, but every checkpoint programme traces back to this result.
Every checkpoint inhibitor, from ipilimumab to pembrolizumab, rests on this idea: the immune system can already recognise cancer and just needs its brakes released. It changed the goal of immunotherapy from vaccinating against tumours to unleashing existing T cells.
Pages like this
not linked directly; found by shared links- PersonJames P. Allison
Shares Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours, Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma, CTLA-4, MD Anderson Cancer Center.
- TrialKEYNOTE-006
Shares CTLA-4, PD-1, Immune checkpoint inhibitors.
- PersonF. Stephen Hodi
Shares Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma, CTLA-4, PD-1, Immune checkpoint inhibitors.
- TargetVISTA
Shares CTLA-4, PD-1, Immune checkpoint inhibitors, Prostate cancer.
- PersonPrimo N. Lara Jr.
Shares Renal cell carcinoma, Bladder & urothelial cancer, Prostate cancer.
- PersonJames L. Gulley
Shares Bladder & urothelial cancer, Immune checkpoint inhibitors, Prostate cancer.
- InstitutionCedars-Sinai Cancer
Shares Renal cell carcinoma, Bladder & urothelial cancer, Immune checkpoint inhibitors.
- PersonDingwei Ye
Shares Renal cell carcinoma, Bladder & urothelial cancer, Prostate cancer.